BRAF and colorectal carcinoma: Previously, we developed a low cost and fully automatable, molecular inversion probe (MIP) and amplicon sequencing assay that multiplexes MSI and BRAF analyses in a single CRC molecular test for LS screening [10] and ICI therapy [21].